Journal of Antimicrobial Chemotherapy · 1998 · 57 citations · 8 references
MedicineMedicinal ChemistryPharmacologyAntimicrobial PharmacologyMolecular PharmacologyPharmacodynamicsAntibacterial AgentsAntibacterial PharmacologyEnzyme InhibitionMolecular Drug Susceptibility TestingMycobacterium Tuberculosis InfectionPhenotypic Drug Susceptibility TestingTuberculosis Drug DevelopmentTuberculosis Drug Resistance
Twelve lipophilic 2,4-diamino-5-methyl-5-deazapteridine derivatives and trimethoprim were evaluated for activity against Mycobacterium tuberculosis and Mycobacterium avium in vitro. Six of the compounds had MICs of < or =12.8 mg/L and < or =1.28 mg/L against M. tuberculosis and M. avium, respectively; trimethoprim MICs were >128 mg/L and >12.8 but < or =128 mg/L, respectively. Two compounds, with either a 2-methyl-5-methoxy phenyl or 2-methoxy-5-trifluoromethyl phenyl linked at the 6-position of the deazapteridine moiety by a CH2NH bridge, had MICs of < or =0.13 mg/L against M. avium; the two compounds also had apparent I50 values for dihydrofolate reductase of 2 and 8 nM, respectively, compared with an I50 of 400 nM with trimethoprim. Four of the compounds were selectively toxic to mycobacteria as compared with Vero cells. These results demonstrated that lipophilic antifolates can be synthesized which are more active against mycobacteria than trimethoprim and which possess selective toxicity.
8
L A Collins, Scott G. Franzblau · Antimicrobial Agents and Chemotherapy · 1997 · 1.6K citations · Full text
Veterinary Medicine, Infectious Diseases, Antimicrobial Pharmacology +7
James R. Piper, Cheryl A. Johnson, Charles A. Krauth et al. · Journal of Medicinal Chemistry · 1996 · 48 citations · Full text